### P 1  VIRAL AND MOLECULAR BIOLOGY

| **P 1-1** | The development of a primary cell model for the investigation of double strand DNA repair in HPV-associated gynaecological cancers | Cossar L. | UK |
| **P 1-2** | Analysis of human papillomavirus and DNA ploidy in cervical lesions | Pogere A. | Brazil |
| **P 1-3** | High throughput molecular testing for HPV: performance of the Onclarity™ HPV assay on a new high throughput system versus the Viper™ LT system | Shah R. | USA |

### P 2  EPIDEMIOLOGY AND NATURAL HISTORY

| **P 2-1** | Human papillomavirus infection in gynecological cancers in Latvia: from the epidemiological data to clinical impact | Borruto F. | Monaco |
| **P 2-2** | Breast cancer associated to HPV and concomitant partner with a history of penile cancer | Sales V. | Brazil |
| **P 2-3** | A cohort study on the cervical precancerous lesion demographic character, prevalence and practice on its association with Human Papillomavirus Virus subtypes between Iranian populations | Hasanzadehifomrad M. | Iran |
| **P 2-4** | High risk human papillomavirus in a group of Portuguese women | Verdasca N. | Portugal |
| **P 2-5** | Cervical adenocarcinomas, human papillomavirus types and association with age; an association study | Rabelo-Santos S. | Brazil |
| **P 2-6** | Human papillomavirus (HPV) cytology and genotype distribution in vaccinated women from East-Flanders, Belgium | Vallaey S. | Belgium |
| **P 2-7** | Prevalence of human papillomavirus among adolescents after introduction of school-based HPV vaccination in Norway | Campbell S. | Norway |
| **P 2-8** | A clinical audit on HPV prevalence amongst cervical lesions in Malta | Spiteri M. | Malta |
| **P 2-9** | Analysis of HPV 18 diversity among women with different morphology diagnosis in Russian Federation | Dmitriyukova M. | Russia |
| **P 2-10** | Prevalence of high-risk HPV in a region of Portugal: analysis of data from patients referred from cervical cancer screening | Pereira J. | Portugal |
| **P 2-11** | Significant disparity in the prevalence of low-risk but not high-risk HPV genotypes among HIV positive MSMs as compared to healthy women | Borena W. | Austria |
| **P 2-12** | Phylogenetic characterisation of high risk human papillomavirus genotypes isolated from Gambian women | Bah Camara H. | UK |
| **P 2-13** | Deciphering the kinetics and ecology of human papillomavirus (HPV) genital infections in young women | Rahmoun M. | France |
| **P 2-14** | Identifying bias caused by multi-type HPV infections in type-specific progression parameter estimates | Suomenrinne-Nordvik A. | Finland |
| **P 2-15** | Incidence of cervical lesions associated with human papillomavirus infection in women living in tributary communities of Amazonas river - Brazil | Zonta M. | Brazil |
| **P 2-16** | Epidemiology of oral HPV injection in transit tissue | Williams R. | UK |

### P 5  HPV PROPHYLACTIC VACCINES

| **P 5-1** | Prevalence and genotyping of HPV in a Portuguese vaccinated population | Teresa R. | Portugal |
| **P 5-2** | Prevalence of HPV infection and hypothetical effect of the nonavalent vaccine in western Huesca (Spain) | Queipo. Gutierrez F. | Spain |
| **P 5-3** | Association between PAP abnormalities and HPV infection in participants in HPV vaccine clinical trials | Joshi A. | USA |
| **P 5-4** | Impact and effectiveness of the quadrivalent human papillomavirus vaccine on oral and anal HPV infections and recurrent respiratory papillomatosis | Drury A. | France |
| **P 5-5** | A systematic literature review update of the impact and effectiveness of the quadrivalent human papillomavirus vaccine on cervical abnormalities | Kuter B. | USA |
| **P 5-6** | Prevention of HPV-associated recurrence of CIN3: the experience of vaccination against HPV | Trushina O. | Russia |
| **P 5-7** | Very low prevalence of vaccine human papillomavirus (HPV) among vaccinated sexually active young women: a study in eastern France | Bretagne C. | France |
P 6  HPV THERAPEUTIC VACCINES

P 6-1  Therapeutic human papillomavirus vaccines in head and neck cancer: a systematic review of current clinical trials

P 6-2  Efficacy of HPV vaccine in preventing of increasing cervical lesion in abnormal PAP test

Schneider K.  Denmark
Karimi-Zarchi M.  Iran

P 8  HPV TESTING

P 8-1  Luminex and multiplex qPCR for detecting HPV genotypes in urine samples

P 8-2  HPV infection in women and men from infertile couples and gamete donors

P 8-3  Pitfalls in HPV68a detection

P 8-4  Validation of a commercial HPV testing assay to detect HPV16 in anal cytology specimens from a high-risk patient population

P 8-5  HPV colonization in cervical secretions versus infection in cervical cancer tissue

P 8-6  HPV test and improvement in cytology efficacy in western Huesca (Spain)

P 8-7  Co-test value after loop electrosurgical excision in high grade cervical lesions

P 8-8  Performance of the semi-quantitative human papillomavirus genotyping test Anyplex II HPV28 in a referral population

P 8-9  Atypical glandular cells on PAP testing and its correlations to HPV

P 8-10  Evaluation of a custom configured Tecan Evo Freedom worktable set up for pre-analytic processing of Preservcyt LBC samples for high risk HPV DNA testing in primary screening and triage

P 8-11  Evaluation of p16INK4A and Ki-67 expression and association with human papillomavirus infection in carriers of penile cancer in Brazil

P 8-12  HPV and CMV infection among HIV-positive women in some countries of Eastern Europe and Central Asia

P 8-13  Ethiopathogenesis of adenocarcinoma in situ cervix (AIS). Is there a difference in relation to squamous intraepithelial lesions (SIL)?

P 8-14  Preliminary evaluation of the high + low papillomastrip assay with Colli-Pee™ collected UCM preserved urine

P 8-15  Clinical significance of HC2 test results in grey zone range used in Slovenian cancer screening program ZORA

Gilfillan S.  Norway
Koudelakova V.  Czech Republic
Jaworek H.  Czech Republic
Guo M.  USA
Vaitkien D.  Lithuania
Ramon Y Cajal J.  Spain
Vicente A.  Portugal
Baasland I.  Norway
Coutinho F.  Portugal
Smith D.  UK
Carneiro M.  Brazil
Popova A.  Russia
Zivadinovic R.  Serbia
Vorsters A.  Belgium
Varl J.  Slovenia

P 9  HPV SCREENING

P 9-1  Acceptability of point of care HPV-based cervical screening: a qualitative systematic review

P 9-2  Evaluation of the efficacy of the treatment of vaginal intraepithelial neoplasia in public hospital in Sao Paulo, Brazil

P 9-3  New molecular markers in HPV infection risk stratification: systematic review

P 9-4  High prevalence and concordance of anal and cervical HPV genotype detection

P 9-5  Non-16/18 HPV genotypes predominant in biopsy samples with high grade squamous intraepithelial lesions in women with preceding negative HPV tests

P 9-6  Organization of in-depth examination for diagnostic cervical cancer of Rostov region female population

P 9-7  Incidence of human papillovirus infection in riverside women of afluentes Amazonas river - Brazil

P 9-8  Countries of Eastern Europe and Central Asia: the situation of HPV infection in HIV-positive women

P 9-9  Distribution of genotypes in a mRNA HPV-positive screening population

P 9-10  Urine detection of HPV oncoprotein: is it a new alternative for cervical cancer screening?

P 9-11  HPV screening among HIV-positive women in Albania

P 9-12  HPV infection among HIV-positive men: a five-year revised experience of a diagnosis laboratory

Camara H.  Australia
Tacla M.  Brazil
Figueiredo Dias M.  Portugal
Thies S.  Germany
Ge Y.  USA
Dimitriadi T.  Russia
Roque K.  Brazil
Deulina M.  Russia
Helenius G.  Sweden
Oliveira C.  Brazil
Shundi L.  Albania
Sousa M.  Portugal
POSTERS

P 10 SELF-SAMPLING

P10-1 Social economic determinants for cervical cancer screening non-attenders offered HPV self-sampling as an alternative to ordinary screening: who accepted and who did not? Vik Hessner M. Denmark

P10-2 Performance of 6 methylation markers tested on self-collected dry samples feasibility study Klischke L. Germany

P10-3 Comparison between the self-sampling and urine for the determination of HPV in high risk population of our medium Fiol Ruiz G. Spain


P10-5 Evaluation of the INNO-LiPA HPV genotyping EXTRA II on UCM preserved first-void urine Jannes G. Belgium

P10-6 Usability of the Colli-Pee™: a first-void urine self-sampling device Provinciael T. Belgium

P10-7 Will HPV self-sampling diminish the social inequalities in the Flemish cervical cancer screening program? Kellen E. Belgium

P10-8 Prevalence of human papillomavirus on the hands of health professionals Costa J. Portugal

P 11 GENOTYPING

P 11-1 Prevalence of human papilloma virus in vulnerable women from Bucaramanga, Colombia Torrado García L. Colombia

P 11-2 Retrospective analysis of the HPV genotype and estimated impact of the vaccine against HPV in southern Spain Rodriguez-Iglesias M. Spain

P 11-3 Performance of three HPV genotyping assays on formalin-fixed paraffin-embedded cervical samples Kristiansen-Haugland H. Norway

P 11-4 Assessment of isothermal amplification Ampfire assay for detection and genotyping of HPV in formalin-fixed paraffin-embedded head and neck cancer samples Paytubi S. Spain

P 12 MOLECULAR MARKERS

P 12-1 Inter-observer agreement on interpretation of dual stained p16/Ki-67 samples in a HPV positive primary screening population White C. Ireland

P 12-2 Is RNA extraction method crucial for human papillomavirus E6/E7 oncogenes detection? Basaras M. Spain

P 12-3 Detection of high risk HPV types and risk prediction of cervical cancer Fu G. UK

P 12-4 Expression and clinical significance of angiopoietin-1, angiopoietin-2, TIE2 receptor and HPV status in patients with penile carcinomas Saddi V. Brazil

P 12-5 Cervical cancer cell lines membrane proteomics offers new insights in the disease mechanisms Pappa K. Greece

P 12-6 Could methylation assays for early detection of CIN2+ lead to overtreatment? – case report Costa F. Portugal

P 12-7 XRCC1 rs1799782 and ERCC2 rs13181 polymorphisms as potential prognostic and predictive factors in cervical cancer patients Nogueira A. Portugal

P 12-8 p16 in the histological diagnosis of the intraepithelial neoplasias of the cervix: evaluation and proposals for use Forteza A. Spain

P 12-9 Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology Peeters E. Belgium

P 12-10 Detection of potential biomarkers in the high grade anal intraepithelial neoplasia from HIV/HPV co-infected MSM Nicol A. Brazil
**P 13 SCREENING METHODS**

**P 13-1** Evaluation of an immunoassay for high-grade cervical pre-cancer screening among women presenting for colposcopy in Brazil

Andrews J. USA

**P 13-2** Diagnostic concordance between cytology, colposcopy and biopsy in cervical pathology in Funchal, Portugal

Domingos C. Portugal

**P 13-3** Suitability of the training program for evaluation of p16/Ki-67 staining for laboratory staff without skills in gynecological cytology and immunocytochemistry

Kloboves Prevodnik V. Slovenia

**P 13-4** Coverage of PAP test and adherence to alternative methods of cervical cancer prevention in Barretos city, São Paulo: preliminary results form a population-based study

Rocha A. Brazil

---

**P 14 LIQUID BASED CYTOLOGY**

**P 14-1** The evaluation of p16/Ki-67 dual stain cytology as an adjunctive tool triaging women with ASCUS and LSIL cytology

Mentzelopoulou P. Greece

---

**P 15 AUTOMATION IN CYTOLOGY**

**P 15-1** Automated high-throughput cytology using Rapid Evaporative Ionization Mass Spectrometry (REIMS)

Kyrgiou M. UK

---

**P 16 METHYLATION**

**P 16-1** Clinical performance of a quantitative specific methylation PCR test on a cohort of HPV positive women aged ≥ 30 years

Mlakar J. Slovenia

**P 16-2** DNA methylation panel for the triage of HPV positive women in a primary screening population

Reynolds S. Ireland

---

**P 19 NEW TECHNOLOGIES**

**P 19-1** Comparison of visual and cytology cervical cancer screening in Maharashtra, India

Misrahi Y. Israel

**P 19-2** Human uterine cervix-on-a-chip: establishing the first in vitro model to study the development of cervical carcinoma and human papilloma virus mechanism of action

Gaslain Y. Spain

**P 19-3** Evaluation of a novel isothermal amplification assay for rapid HPV DNA detection and genotyping

Kleeman M. UK

**P 19-4** A novel approach to identify proteins by gel-based proteomics in residual cervical cytology samples during cervical carcinogenesis

Rosini S. Italy
## POSTERS

### P 20  DIAGNOSTIC PROCEDURES / MANAGEMENT

| P 20-1 | Values of HPV status, sample margins, and endocervical curettement after LLETZ conization as prognostic factors for successful treatment | Butorac D. | Croatia |
| P 20-2 | HSIL management in young women | Marques M. | Portugal |
| P 20-3 | Connection between the frequency of preventive gynecological examinations and cervical cancer detection: a case-control study | Zarechentseva N. | Russia |
| P 20-4 | Comparative performance of HPV DNA and messenger RNA tests in the post-leep test-of-cure setting | Ogilvie G. | Canada |
| P 20-5 | Human papilloma virus in urine and bladder cancer risk: a systematic review and meta-analysis | Garcia-Rojo D. | Spain |
| P 20-6 | Colposcopic and histological findings in women with low grade intraepithelial lesion (LSIL) submitted to ZT excision | Pacheco A. | Portugal |
| P 20-7 | Cytomorphological parallels of pathology of glandular epithelium of cervix among reproductive age women | Dubrovna S. | Russia |

### P 21  COLPOSCOPY

| P 21-1 | Practice of colposcopy at the gynecological and obstetrical clinic of CHU Aristide Dantec of Dakar (Senegal) from 2005 to 2017 (Senegal): about 1559 cases | Gassama O. | Senegal |
| P 21-2 | The accuracy of colposcopy utilizing RCI or Swede score combined with adjunct hrHPV for prediction of high-grade intraepithelial neoplasia (CIN2+) in the patients with ASC-US, ASC-H, LSIL and HSIL Pap smears on Bethesda classification | Zubor P. | Slovakia |

### P 22  CERVICAL NEOPLASIA

| P 22-1 | Use and results of a coriolus versicolor-based vaginal gel in women HPV+ and/or abnormal PAP smear attended in a regional Spanish hospital. Preliminary analysis | Gajino C. | Spain |
| P 22-2 | Cervical HPV and solid organ transplant - a risky conundrum | Miranda-Silva C. | Portugal |
| P 22-3 | The role of HPV E6/E7 oncoproteins in early diagnostic of cervical precancerous lesions | Jermakova I. | Latvia |
| P 22-4 | Cervical cancer in Catalonia. A systematic survey of new cases in a general hospital. | Rodrigo M. | Spain |
| P 22-5 | Genital prolapse associated with cervical cancer - a case report | Estevinho C. | Portugal |
| P 22-6 | Coriolus versicolor vaginal gel in the treatment of high-risk positive HPV patients | Riera M. | Spain |
| P 22-7 | Efficacy of a coriolus versicolor-based vaginal gel in high risk HPV+ women. Preliminary results. | Marín Ortiz E. | Spain |
| P 22-8 | Positive margins after loop electrosurgical excision procedure for cervical intraepithelial neoplasia: expectant management and follow-up | Ormonde M. | Portugal |
| P 22-9 | Evaluating ErbB receptor profile in young patients with cervical cancer | Michail G. | Greece |
| P 22-10 | Rhabdomyosarcoma of the cervix – case report | Mitran M. | Romania |
| P 22-11 | Cervical cancer screening program in Lithuania | Rimiene J. | Lithuania |
P 23  VAGINAL NEOPLASIA
P 23-1  High-grade vaginal intraepithelial neoplasia - a retrospective study  Pinto A.  Portugal
P 23-2  VAIN - a 7 years hospital experience  Martins M.  Portugal
P 23-3  Melanoma maligno de vagina  Chaves J.  Brazil

P 24  VULVAR DISEASES AND NEOPLASIA
P 24-1  Vulvar Intraepithelial Neoplasia: retrospective study of 10 years  Marques C.  Portugal
P 24-2  CO2 laser treatment in VIN lesions: what is its role?  Pedrosa I.  Portugal

P 25  ANAL NEOPLASIA
P 25-1  Anal cancer screening compliance and knowledge among HIV positive MSM in the Czech Republic  Klubalova B.  Czech Republic
P 25-2  Does sampling strategy influence cytological and genetic findings in anal cancer screening of patients at risk?  Nemcova J.  Czech Republic
P 25-3  Anal intraepithelial lesions in women with high-grade cervical intraepithelial neoplasia  Cominho J.  Portugal
P 25-4  DNA-HPV PCR: a tool to indicate anal cytology in immunosuppressed women  Eleutério Junior J.  Brazil
P 25-5  Anal cancer risk among people with HIV infection in the United States  Colon-Lopez V.  Puerto Rico

P 26  ORAL HPV INFECTION
P 26-1  HPV in oral cavity of patients with breast cancer  Pinheiro D.  Brazil
P 26-2  Prevalence of oral HPV infection in a prospective cohort of HIV-infected and uninfected men who have sex with men: the Ohmar project  Dona M.  Italy

P 27  HPV AND OROPHARYNX / HEAD AND NECK CANCER
P 27-1  High risk human papillomavirus genotypes detected in recurrent respiratory papillomatosis by linear array and NSG.  Martínez Salazar M.  Mexico
P 27-2  Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours.  Stevenson A.  UK
P 27-3  Three cases of HPV-related oropharyngeal cancer with good course despite noncompletion of (chemo) radiotherapy  Kishikawa T.  Japan
P 27-4  Absence of disruptive TP53 mutations in high-risk human papillomavirus-driven neck squamous cell carcinoma from unknown primary  Boscolo-Rizzo P.  Italy
P 27-5  Psychological impact of patients living with head and neck cancer: a systematic literature review  Yen G.  USA
P 27-6  Human papillomavirus infection in sino-nasal inverted papilloma: an Italian epidemiological study  Muresu N.  Italy
P 27-7  Differences in the prognosis of HPV16 positive patients with squamous cell carcinoma of head and neck according to viral load and expression of p16  Biesaga B.  Poland
POSTERS

P 28  HPV AND ASSOCIATED SKIN DISEASES
P 28-1 Development of G-quadruplex mediated HPV antiviral drugs  
Cruz C.  Portugal

P 29  GENITAL WARTS
P 29-1 Anogenital warts in pregnancy  
Geraldes F.  Portugal

P 30  SEXUALLY TRANSMITTED DISEASES AND HIV INFECTION
P 30-1 HIV infected pregnant women data completeness from state of Espirito Santo Brazil public database  
Caldas J.  Brazil
P 30-2 Papanicolaou (PAP) smear changes and cervical HPV prevalence in women living with human immunodeficiency virus  
Águas F.  Portugal
P 30-3 Epidemiology of HPV anal infection in person with HIV attending a sexually transmitted infection clinic in Brazil  
Tosato Boldrini N.  Brazil
P 30-4 Retrospective cohort study of men who have sex with men that are infected by the human immunodeficiency virus and were submitted to human papillomavirus screening in the anal canal  
Vale F.  Portugal

P 31  CONVENTIONAL THERAPIES
P 31-1 3-year study of excision of the cervical transformation zone in women in Madeira island - are we meeting the quality indicators?  
Gomes R.  Portugal
P 31-2 Obstetric outcomes after excision of the cervical transformation zone a retrospective 8-year study  
Oliveira I.  Portugal
P 31-3 Placental growth restriction in HIV-infected women as a sign of early pregnancy aggression  
Reis H.  Brazil

P 32  ECONOMICS AND MODELLING
P 32-1 Costs and healthcare resource utilization for cervical conization in mid-adult women in the United States  
Perez Amaya G.  USA
P 32-2 Incidence and treatment-related economic burden of HPV-related cervical, vulvar, vaginal, and anal cancers in the US  
Elbasha E.  USA
P 32-3 Cost-effectiveness of the newly implemented HPV-based screening programme in the Netherlands  
Naslazi E.  Netherlands
P 32-4 The effect of an HPV gender-neutral vaccination program on vaccine hesitancy  
Olsen J.  Denmark
<table>
<thead>
<tr>
<th>P 33</th>
<th>ADVOCACY, ACCEPTABILITY AND PSYCHOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 33-1</td>
<td>Building collaborations among HPV vaccination stakeholders: examining the impact of a national HPV roundtable</td>
</tr>
<tr>
<td>P 33-2</td>
<td>The association between maternal history of cervical cancer and HPV vaccination of children</td>
</tr>
<tr>
<td>P 33-3</td>
<td>HPV knowledge among European adolescents and their parents: results from a systematic literature review</td>
</tr>
<tr>
<td>P 33-4</td>
<td>HPV vaccine acceptance among European adolescents and their parents: results from a systematic literature review</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P 34</th>
<th>HEALTH EDUCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 34-1</td>
<td>Insights on HPV vaccination in the United States from mothers' comments on facebook posts in a randomized trial</td>
</tr>
<tr>
<td>P 34-2</td>
<td>Willingness of oral health students to train and administer the HPV vaccine in the dental setting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P 36</th>
<th>PUBLIC HEALTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 36-1</td>
<td>Issues arising at launch of anti-HPV mass vaccination campaign in 2018: case of Estonia</td>
</tr>
<tr>
<td>P 36-2</td>
<td>Evolution of gender-neutral HPV vaccination in national immunization programs around the world</td>
</tr>
<tr>
<td>P 36-3</td>
<td>Recall and patient navigation to increase cervical cancer screening among un-/under-screened women in a U.S. safety net healthcare system: interim results</td>
</tr>
<tr>
<td>P 36-4</td>
<td>Results from ongoing trials of mobile web apps to improve HPV vaccine uptake</td>
</tr>
<tr>
<td>P 36-5</td>
<td>Adherence to HPV vaccination is associated with participation in cervical cancer screening - a Danish national register-based cohort study</td>
</tr>
<tr>
<td>P 36-6</td>
<td>Papillomavirus transmission and prevention and effective disinfection</td>
</tr>
</tbody>
</table>

Abstracts are available for download at: www.eurogin.com/2018